

Ref. No: 2699
Date: 14/07/26
Subject: Products given

REQUEST

I would like to request the following information for Q2 2026 (April–June 2026).

Please provide total volume (IU/mg) and, where available, total number of patients treated with the following products:

- NovoSeven (eptacog alfa)
- Cevenfacta (eptacog beta)
- FEIBA (anti-inhibitor coagulant complex)
- Obizur (susoctocog alfa)
- Hemlibra (emicizumab) (*haemophilia A inhibitor patients only*)

Where feasible from existing records, I would also welcome any available breakdown of these patient numbers and/or volumes by indication. For example:

- haemophilia A with inhibitors
- haemophilia B with inhibitors
- Acquired haemophilia (AHA)
- Glanzmann thrombasthenia
- Factor VII deficiency
- other (please specify)

Partial breakdowns (e.g. for only some indications) are welcome. If this level of detail is not routinely captured, please provide the data in the closest available format, or without any indication breakdown.

RESPONSE

Zero requests received / issued.